Pharnext announced last night that it had filed an application with the Paris Commercial Court to open judicial liquidation proceedings.

This decision comes as the biotech company was no longer in a position to finance its activities beyond July 15, following the failure of its clinical trials in Charcot disease.

The judicial review hearing has been set for August 22, with Pharnext warning that any proceeds from the sale of assets should not enable a payment to be made to its shareholders.

Copyright (c) 2024 CercleFinance.com. All rights reserved.